Vancomycin Therapeutic Drug Monitoring in Patients on Continuous Renal Replacement Therapy: a Retrospective Study

Overview

Journal J Int Med Res

Publisher Sage Publications

Specialty General Medicine

Date 2022 Sep 30

PMID 36177821

Authors

Yuyan Liu

Li Jiang

Ran Lou

Meiping Wang

Quan Si

Affiliations

Soon will be listed here.

Abstract

Objectives: This study aimed to investigate vancomycin therapeutic drug monitoring (TDM) in patients on continuous renal replacement therapy (CRRT) and explore the risk factors for exceeding the target concentration.

Methods: This retrospective study enrolled patients aged ≥18 years who were admitted to the intensive care unit and treated with ≥3 intravenous vancomycin doses during CRRT, and who underwent vancomycin TDM. Demographic and other information were collected. Multivariate logistic regression was used assess the risk factors for exceeding the target concentration.

Results: Sixty-nine patients were included, and 40.6% patients underwent TDM. Additionally, 14.5% of patients reached the optimal concentration, and 87.5% of patients who exceeded the target received a daily dose adjustment. The cumulative dose of vancomycin and serum albumin were risk factors for exceeding the target concentration in patients on CRRT.

Conclusions: Patients on CRRT did not meet the optimal vancomycin management; <50% of the patients routinely received vancomycin TDM, and <15% achieved the optimal concentration. Fewer patients in the subtherapeutic group received a daily dose adjustment than those who exceeded the target concentration. Cumulative vancomycin and serum albumin doses before TDM were the risk factors for exceeding the target concentration in CRRT patients.

Citing Articles

Therapeutic Drug Monitoring of Vancomycin in Hemodialysis Patients in a Hospital in North-East Romania.

Cretu A, Mititiuc L, Lungu I, Mihaila M, Dima I, Covic A Antibiotics (Basel). 2025; 14(1.

PMID: 39858320 PMC: 11762674. DOI: 10.3390/antibiotics14010034.

References

Petejova N, Martinek A, Zahalkova J, duricova J, Brozmannova H, Urbanek K . Vancomycin pharmacokinetics during high-volume continuous venovenous hemofiltration in critically ill septic patients. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2012; 158(1):65-72. DOI: 10.5507/bp.2012.092. View

Chen J, Huang X, Lin Z, Li C, Ding H, Du J . Case Report: Monitoring Vancomycin Concentrations and Pharmacokinetic Parameters in Continuous Veno-Venous Hemofiltration Patients to Guide Individualized Dosage Regimens: A Case Analysis. Front Pharmacol. 2021; 12:763575. PMC: 8695924. DOI: 10.3389/fphar.2021.763575. View

Chen J, Li S, Wang Q, Wang C, Qiu Y, Yang L . Optimizing Antimicrobial Dosing for Critically Ill Patients with MRSA Infections: A New Paradigm for Improving Efficacy during Continuous Renal Replacement Therapy. Pharmaceutics. 2022; 14(4). PMC: 9031498. DOI: 10.3390/pharmaceutics14040842. View

Khwaja A . KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012; 120(4):c179-84. DOI: 10.1159/000339789. View

Li L, Li X, Xia Y, Chu Y, Zhong H, Li J . Recommendation of Antimicrobial Dosing Optimization During Continuous Renal Replacement Therapy. Front Pharmacol. 2020; 11:786. PMC: 7273837. DOI: 10.3389/fphar.2020.00786. View

Covajes C, Scolletta S, Penaccini L, Ocampos-Martinez E, Abdelhadii A, Beumier M . Continuous infusion of vancomycin in septic patients receiving continuous renal replacement therapy. Int J Antimicrob Agents. 2013; 41(3):261-6. DOI: 10.1016/j.ijantimicag.2012.10.018. View

Oda K, Jono H, Kamohara H, Nishi K, Tanoue N, Saito H . Development of Vancomycin Dose Individualization Strategy by Bayesian Prediction in Patients Receiving Continuous Renal Replacement Therapy. Pharm Res. 2020; 37(6):108. DOI: 10.1007/s11095-020-02820-0. View

Lin H, Bukovskaya Y, de Moya M, Lee J, Schmidt U . Vancomycin continuous infusion versus intermittent infusion during continuous venovenous hemofiltration: slow and steady may win the race. Ann Intensive Care. 2015; 5:10. PMC: 4434240. DOI: 10.1186/s13613-015-0048-x. View

Rybak M, Lomaestro B, Rotschafer J, Moellering Jr R, Craig W, Billeter M . Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2008; 66(1):82-98. DOI: 10.2146/ajhp080434. View

10.

Van Der Heggen T, Buyle F, Claus B, Somers A, Schelstraete P, De Paepe P . Vancomycin dosing and therapeutic drug monitoring practices: guidelines versus real-life. Int J Clin Pharm. 2021; 43(5):1394-1403. DOI: 10.1007/s11096-021-01266-7. View

11.

Lewis S, Mueller B . Development of a vancomycin dosing approach for critically ill patients receiving hybrid hemodialysis using Monte Carlo simulation. SAGE Open Med. 2018; 6:2050312118773257. PMC: 5952280. DOI: 10.1177/2050312118773257. View

12.

Roberts D, Liu X, Roberts J, Nair P, Cole L, Roberts M . A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics. Crit Care. 2015; 19:84. PMC: 4404619. DOI: 10.1186/s13054-015-0818-8. View

13.

Ye Z, Tang H, Zhai S . Benefits of therapeutic drug monitoring of vancomycin: a systematic review and meta-analysis. PLoS One. 2013; 8(10):e77169. PMC: 3799644. DOI: 10.1371/journal.pone.0077169. View

14.

Ackerman B, Taylor E, Olsen K, Pappas A . Vancomycin serum protein binding determination by ultrafiltration. Drug Intell Clin Pharm. 1988; 22(4):300-3. DOI: 10.1177/106002808802200404. View

15.

Al-Maqbali J, Al Shukri Z, Sabahi N, Al-Riyami I, Al Alawi A . Vancomycin Therapeutic Drug Monitoring (TDM) and Its Association with Clinical Outcomes: A Retrospective Cohort. J Infect Public Health. 2022; 15(5):589-593. DOI: 10.1016/j.jiph.2022.04.007. View

16.

Smit C, Wasmann R, Goulooze S, Wiezer M, van Dongen E, Mouton J . Population pharmacokinetics of vancomycin in obesity: Finding the optimal dose for (morbidly) obese individuals. Br J Clin Pharmacol. 2019; 86(2):303-317. PMC: 7015748. DOI: 10.1111/bcp.14144. View

17.

Roberts J, Joynt G, Lee A, Choi G, Bellomo R, Kanji S . The Effect of Renal Replacement Therapy and Antibiotic Dose on Antibiotic Concentrations in Critically Ill Patients: Data From the Multinational Sampling Antibiotics in Renal Replacement Therapy Study. Clin Infect Dis. 2020; 72(8):1369-1378. DOI: 10.1093/cid/ciaa224. View

18.

Kortge A, Majcher-Peszynska J, Heskamp B, Wasserkort R, Mitzner S . Antibiotics Removal by Continuous Venovenous Hemofiltration with a Novel Asymmetric Triacetate Membrane Hemofilter: An in vitro Study. Blood Purif. 2021; 50(6):899-905. DOI: 10.1159/000513417. View

19.

Wahby K, Cunmuljaj L, Mouabbi K, Almadrahi Z, Wilpula L . Evaluation of dosing strategies and trough concentrations of vancomycin in patients undergoing continuous venovenous hemofiltration. Pharmacotherapy. 2021; 41(7):554-561. DOI: 10.1002/phar.2535. View

20.

Bakke V, Sporsem H, von der Lippe E, Nordoy I, Lao Y, Nyrerod H . Vancomycin levels are frequently subtherapeutic in critically ill patients: a prospective observational study. Acta Anaesthesiol Scand. 2017; 61(6):627-635. PMC: 5485054. DOI: 10.1111/aas.12897. View